{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Colorectal&page=31", "query": { "condition": "Carcinoma, Colorectal", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 2788, "total_pages": 279, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Colorectal&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Colorectal&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T14:10:29.578Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06728072", "title": "Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "CRC" ], "interventions": [ { "name": "Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2025-03-07", "completion_date": "2035-07-01", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 2, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06728072" }, { "nct_id": "NCT00303875", "title": "Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Prostate Cancer" ], "interventions": [ { "name": "behavioral dietary and exercise intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "65 Years to 120 Years" }, "enrollment_count": 641, "start_date": "2003-12", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 2, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303875" }, { "nct_id": "NCT01322165", "title": "National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Marfan Syndrome", "Turner Syndrome", "Ehlers-Danlos Syndrome", "Loeys-Dietz Syndrome", "FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation", "Bicuspid Aortic Valve Without Known Family History", "Bicuspid Aortic Valve With Family History", "Bicuspid Aortic Valve With Coarctation", "Familial Thoracic Aortic Aneurysm and Dissections", "Shprintzen-Goldberg Syndrome", "Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo", "Other Congenital Heart Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3706, "start_date": "2007-11", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-12-20", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 7, "location_summary": "Honolulu, Hawaii • Baltimore, Maryland • New York, New York + 3 more", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322165" }, { "nct_id": "NCT00522665", "title": "Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "RAD001", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2007-08", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-05-15", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 14, "location_summary": "Chicago, Illinois • Galesburg, Illinois • Bloomington, Indiana + 7 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00522665" }, { "nct_id": "NCT02991196", "title": "Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasm" ], "interventions": [ { "name": "DS-8273a + nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-12-01", "completion_date": "2017-09-22", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Grand Rapids, Michigan • Houston, Texas + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02991196" }, { "nct_id": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Colorectal Carcinoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "ABBV-221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 46, "start_date": "2015-01-09", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-03-30", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 3, "location_summary": "Boston, Massachusetts • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365662" }, { "nct_id": "NCT00019513", "title": "Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer", "Lung Cancer", "Lymphoma", "Pancreatic Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "1998-08", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-23", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019513" }, { "nct_id": "NCT00040391", "title": "A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Diarrhea" ], "interventions": [ { "name": "Investigational drug", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-12-01", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040391" }, { "nct_id": "NCT06811454", "title": "Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression", "Cancer", "Stage III Breast Cancer", "Stage II Breast Cancer", "Stage I Breast Cancer", "Stage III Prostate Cancer", "Stage II Prostate Cancer", "Stage I Prostate Cancer", "Stage III Colorectal Cancer", "Stage II Colorectal Cancer", "Stage I Colorectal Cancer" ], "interventions": [ { "name": "MINDSET", "type": "BEHAVIORAL" }, { "name": "Enhanced Usual Care (EUC)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 76, "start_date": "2026-08-03", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06811454" }, { "nct_id": "NCT04616183", "title": "LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Recurrent Colorectal Carcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "ERK1/2 Inhibitor LY3214996", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-12-02", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T14:10:29.578Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616183" } ] }